262.00
0.00
(0.00%)
At close: February 20 at 8:33:36 AM CST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 4 | 6 | 5 |
| Avg. Estimate | 38.7M | 43.74M | 173.04M | 201.9M |
| Low Estimate | 37M | 41.8M | 169.7M | 178.74M |
| High Estimate | 40.5M | 45.5M | 179M | 250M |
| Year Ago Sales | 37.94M | 56.21M | 227.04M | 173.04M |
| Sales Growth (year/est) | 1.98% | -22.17% | -23.79% | 16.68% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| DNA.MX | -- | -- | -- | -- |
| S&P 500 | 6.79% | 5.59% | 9.06% | 14.11% |
Upgrades & Downgrades
| Maintains | TD Cowen: Buy to Buy | 9/20/2024 |
| Maintains | BTIG: Sell to Sell | 8/23/2024 |
| Maintains | Goldman Sachs: Sell to Sell | 7/9/2024 |
| Maintains | BTIG: Sell to Sell | 6/26/2024 |
| Downgrade | BTIG: Neutral to Sell | 5/15/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 5/15/2024 |